Healthy Q2 and H1; resulting in consecutive guidance upgrade
04/08/22 -"DiaSorin released healthy Q2 results. While, as expected, non-COVID-19 offerings continued to do well, slower-than-expected moderation in COVID-19 testing sales was a pleasant surprise – also ..."
Pages
66
Language
English
Published on
04/08/22
You may also be interested by these reports :
03/08/26
Our TP has been cut slightly, reflecting an update to the model (net debt, and updated market parameters), with no change to the operational ...
03/08/26
Smart glasses development continues to erode margins. We will take a more conservative view of the company and revise our long-term margin ...
02/08/26
DiaSorin’s Q2 profitability surpassed expectations. Despite weak respiratory sales and challenges in China, revenue grew by mid-single digits. All ...
31/07/26
Siemens Healthineers’ Q3 sales slightly missed expectations, though profitability met forecasts. The Precision Therapy and Imaging segments reported ...